DexCom, Inc. · NASDAQ:DXCM

DexCom — Investor Presentation (July 2024)

24 slides from DexCom's investor presentation, July 2024

  1. Slide 1: Dexcom Investor Presentation July 2024

    Dexcom Investor Presentation July 2024

  2. Slide 2: Safe harbor statement

    Safe harbor statement This presentation contains “forward-looking statements” that are based on our management’s beliefs and assumptions and on information available to management as of July 25, 2024. We intend for such forward-looking statements to be covered by the safe harbor provisions for forwa

  3. Slide 3: A global crisis that remains uncontrolled

    A global crisis that remains uncontrolled Diabetes diagnosis and cost Adults (aged 20-79) with diabetes globally1 People diagnosed with diabetes 783m have ~2.6x higher expenses in 2045E than those without2 537m in 2021 463m in 2019 151m in 2000 More than 1 in 4 US health care dollars are spent on pe

  4. Slide 4: Intermittent glucose monitoring is not enough for diabetes management

    Glucose (mg/dl) 340 SMBG* 320 300 280 260 Intermittent 240 220 glucose monitoring 200 180 is not enough for 160 140 diabetes 120 Target Glucose Range management… 100 80 60 40 20 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hours) *As compared to Self Monitoring of Blood Glucose (SMBG) 4

  5. Slide 5: …and CGM has become standard of care for all stages of insulin-use

    Glucose (mg/dl) 340 320 300 280 260 …and CGM has APPROXIMATELY 17 HOURS ABOVE TARGET RANGE, INCLUDING 240 ~6 HOURS IN SEVERE HYPERGLYCEMIA (>250 mg/dl) 220 become standard 200 180 AVG GLUCOSE: 185 mg/dl of care1 for all 160 140 stages of insulin-use 120 Target 100 Glucose Range 80 60 40 20 0 0 2 4 6

  6. Slide 6: We can do more

    We can do more pexcom 6

  7. Slide 7: Pioneering the CGM industry

    Pioneering the CGM industry First hypo alert setting to increase user safety First approval of dedicated app to share glucose data with a caregiver First to deliver single-digit MARD accuracy levels First approval to send glucose data directly to smartphone First to enable users to monitor glucose l

  8. Slide 8: Empowering people to take control of health

    OUR MISSION Empowering people to take control of health CONFIDENTIAL – DO NOT DISTRIBUTE *Image shown does not include required overpatch. Please be sure to follow instructions for using the overpatch.

  9. Slide 9: 2024 outlook

    2024 outlook FY24 guidance as of July 25, 2024 Objectives & considerations Revenue of • Extending momentum of 2023 launch in type 2 basal and non-insulin hypo populations $4.00 − 4.05 billion • Expansion of Dexcom ONE+ into new geographies ~11 – 13% Organic Growth1 • Summer 2024 launch of Stelo, our

  10. Slide 10: Dexcom G7 is the new standard in CGM technology

    is the new standard in CGM technology Most accurate1 Incredibly simple Most covered2 1) Dexcom, data on file, 2023. 2) Managed Markets Insights & Technology, LLC. MMIT Analytics, October 2023. 10 **Image shown does not include required overpatch. Please be sure to follow instructions for using the o

  11. Slide 11: Building on the G7 standard

    Building on the G7 standard Innovating product design Maximizing volume efficiencies Advancing 15-day Investing in future Extending G7 pump and Dexcom ONE to G7 efforts for G-Series device enhancements connected pen availability form factor 11

  12. Slide 12: Simplified software infrastructure

    S I M P L I F I E D S O F T WAR E INFRASTRUCTURE Single app platform Dexcom ONE on same software infrastructure Global app infrastructure across languages Easy to iterate We have completed software updates almost monthly since launch of G7 12

  13. Slide 13: Iterating software to provide a broader picture of health

    Iterating software to provide a broader picture of health Integrating medication data to show in Ingesting activity data to conjunction with glucose highlight lifestyle management 13 **Image shown does not include required overpatch. Please be sure to follow instructions for using the overpatch.

  14. Slide 14: Connectivity as a competitive advantage

    Connectivity as a competitive advantage Differentiating through hardware and software CUSTOMERS Automated Connected Digital Insulin Delivery Pen Health Apps LOVED ONES HEALTHCARE PROVIDERS 14

  15. Slide 15: Core US market

    Insulin & non-insulin hypoglycemia population Estimated US Insulin CGM Users – All companies* Estimated Reimbursed Population* All Insulin ~7m Core US market Momentum and opportunity IIT remain significant ~4m With coverage for basal insulin users and problematic hypoglycemia there are more people w

  16. Slide 16: Gaining momentum across all segments and channels in US

    Gaining momentum across all segments and channels in US Increased prescriber base by ~40% in 2023 >70% of new scripts written by primary care physicians 16

  17. Slide 17: Driving international growth

    Driving international growth Entering new geographies Reducing administrative barriers Expanding reimbursement Well-positioned to extend Going direct in strategic markets international growth momentum Extending Dexcom ONE+ to additional markets 17

  18. Slide 18: The right portfolio approach to unlock new geographies & expand share

    The right portfolio approach to unlock new geographies & expand share Broad Limited Tiered Reimbursement Markets Reimbursement Reimbursement G-Series G-Series Dexcom ONE Dexcom ONE EXAMPLES: EXAMPLES: EXAMPLES: Germany United Kingdom Italy Bulgaria Japan Spain France Romania Canada Lithuania 18

  19. Slide 19: What is next? 25+ million people

    T O TA L A D D R E S S A B L E M A R K E T There are 25+ million people1 What is next? in the US with type 2 diabetes that have not Extending our growth runway into non-insulin yet progressed to insulin therapy and are not using people with type 2 diabetes at high-risk of hypoglycemia We see an oppo

  20. Slide 20: Reframing what is possible with Dexcom CGM

    Reframing what is possible with Dexcom CGM An example of a Dexcom First patient journey1 Visit One One-Year Visit Two-Year Visit Most Recent Visit (~2.5 Years) 100% In Range 16% Very High 90% In Range 88% In Range Continue Dexcom CGM 34% Discontinue GLP-1 High Time In 100% Range2 Continue Dexcom CGM

  21. Slide 21: CGM adds meaningful clinical value beyond GLP-1 therapy

    CGM adds meaningful clinical value beyond GLP-1 therapy and clinicians want to prescribe these products together… People with uncontrolled Type 2 diabetes % CGM usage for those initiating GLP-1 on semaglutide or tirzepatide1 therapy in each year2 -1.47 Type 2 – Non-Insulin Therapy -0.99 Average CGM

  22. Slide 22: We can do more

    Commercial Wrap We can do more 22

  23. Slide 23: Dexcom's first product targeted for people with diabetes not on insulin

    Dexcom’s first product targeted for people with diabetes not on insulin Custom software Cash-pay option 15-day wear period First CGM cleared for use without a prescription in the US Expected to launch late August 2024 *Dexcom, Stelo, and any related logos and design marks are either registered trade

  24. Slide 24: Where we are, where we are going

    Where we are Where we are going • Type 1 • Type 2 Non-Insulin • Type 2 IIT • Pre-Diabetes • Type 2 Basal-Only • Gestational Diabetes • Type 2 Problematic • Patient Monitoring Hypo (Non-Insulin) • Health & Wellness *Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, and any related logo

Dexcom — Investor Presentation (July 2024) on 6ix